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Abstract
Biomarker measurements can be relatively easy and quick to obtain and they
are useful to investigate whether a compound works as intended on a mechanistic,
pharmacological level. In some situations, it is realistic to assume that patients,
whose post-baseline biomarker levels indicate that they do not sufficiently respond to
the drug, are also unlikely to respond on clinically relevant long term outcomes (such
as time-to-event). However the determination of the treatment effect in the subgroup
of patients that sufficiently respond to the drug according to their biomarker levels
is not straightforward: It is unclear which patients on placebo would have responded
had they been given the treatment, so that naive comparisons between treatment
and placebo will not estimate the treatment effect of interest. The purpose of this
paper is to investigate assumptions necessary to obtain causal conclusions in such a
setting, utilizing the formalism of causal inference. Three approaches for estimation of
subgroup effects will be developed and illustrated using simulations and a case-study.
Keywords: Causal Inference, Estimand, Principal Stratification, Subgroup Analysis, Weight-
ing
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1 Introduction
Biomarker measurements can be relatively easy and quick to obtain, and are useful to
investigate whether a compound works as intended on a mechanistic, pharmacological level.
In some situations, it is plausible to assume that post-baseline biomarker responders are
also more likely to respond better on clinically relevant long term outcomes, which are
often of time-to-event type.
This research is motivated by the CANTOS outcome study in prevention of cardiovas-
cular events (Ridker et al. 2017). Inflammation has been identified as playing a key role in
atherosclerosis, for example in the formation and rupture of atherosclerotic plaques (Hans-
son 2005). The CANTOS trial investigated canakinumab, an anti-inflammatory agent,
against placebo. The primary outcome was the time to a major adverse cardiac (MACE)
event, a composite endpoint consisting of cardiovascular death, non-fatal myocardial in-
farction and stroke, and was statistically significant. In this specific case the biomarker
of interest is a downstream inflammatory marker high sensitivity C-reactive protein (hs-
CRP), where lower values indicate less inflammation. Interest focuses on determination of
the treatment effect for hs-CRP patients that, 3 months after treatment start, were able
to lower hs-CRP below a specific target level.
The determination of the treatment effect in a subgroup of patients that is defined
based on post-baseline biomarker levels in the treatment group (e.g. indicated by reaching
biomarker levels smaller than some threshold) is not straightforward: The biomarker might
have a prognostic effect on the outcome, independent of treatment. For example hs-CRP
is a known prognostic risk factor for cardiovascular events. It is likely that patients who
reach the biomarker target level on treatment also had a better (i.e. smaller) biomarker
measurement at baseline compared to patients, who do not reach the target. A naive
comparison of the biomarker responder subgroup on treatment, to the complete placebo
group will thus likely overestimate the treatment effect. Similarly a naive comparison of
the biomarker responder subgroup patients on treatment, against the biomarker responder
subgroup patients on placebo will also likely be biased. Patients, who reach biomarker
levels below the target on placebo are likely more “healthy” than the biomarker responders
on treatment. So such a comparison would likely underestimate the treatment effect.
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The purpose of this paper is to investigate the assumptions necessary to draw causal
conclusions, using the formal language of causal inference developed over the past decades,
see for example Pearl (2009), Imbens & Rubin (2015) or Herna´n & Robins (2018) for
reviews. “Valid conclusions” here means that the treatment effect should be attributable
to the difference in treatment and not to differences in the two compared populations.
In the causal inference literature there are several papers dealing with related questions
in more detail. The paper Frangakis & Rubin (2002) introduced the term principal strati-
fication. A reference providing a review of many of the recent approaches and developing
new approaches is Ding & Lu (2017). Related references among others are for example
Joffe et al. (2007), Schwartz et al. (2011), Zigler & Belin (2012), Jo & Stuart (2009, 2011),
Stuart & Jo (2015), Kern et al. (2016).
The purpose of this article is to provide a review of the underlying problem and propose
methods that could be utilized in this setting. In Section 2 we utilize causal inference
techniques to express the estimands of interest in terms of quantities that are identifiable
in a randomized clinical trial. In Section 3 we discuss how these quantities can be estimated.
In Section 4 we perform a simulation study to illustrate the proposed methods in a specific
situation. Section 5 illustrates the method for a specific simulated data set. Section 6
concludes.
2 Methods
2.1 Estimand of interest
Assume a randomized trial with a treatment and a placebo arm. Let X denote the treat-
ment indicator, denoting whether a patient was randomized to treatment (x = 1) or placebo
(x = 0). Further let β(x) denote the potential continuous biomarker outcome under treat-
ment x at a specified time T after start of the study. Further let B(x) be the binary
indicator, defined as whether β(x) < β∗ for a target threshold β∗. Let T (x) be the po-
tential event time under treatment x. Here we focus on composite endpoints (a mixture
of non-fatal events and death). The corresponding observed values will be denoted by
β = β(X), B = B(X) and T = T (X), where X is the treatment actually obtained. Let
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Z denote a vector of baseline variables influencing the biomarker and the event time. We
assume in what follows that T is small, so that no events are observed before T . We include
a discussion in Appendix B on how to handle events before time T .
As discussed in the introduction, the population of interest is the subgroup of patients,
that, if given the treatment would be biomarker responders. In terms of the introduced
notation these are the patients with B(1) = 1.
Different summary measures exist to define a treatment effect in terms of time-to-event
outcomes. We focus here on the difference in survival probabilities at a given time-point t
∆(t) = P (T (1) > t|B(1) = 1)− P (T (0) > t|B(1) = 1), (1)
and the difference in restricted mean survival times (Royston & Parmar 2011),
∆RMST,t∗ =
∫ t∗
0
∆(t)dt, (2)
integrated up to a time-point t∗. Here P (T (1) > t|B(1) = 1) and P (T (0) > t|B(1) = 1)
are the survival functions in the subgroup of interest.
Because biomarker response is a post-baseline event in a parallel groups trial, we do
not know which patients on placebo would be a biomarker responder had they received
treatment. Identification of the estimand, and particular P (T (0) > t|B(1) = 1), hence
requires assumptions. In terms of the draft ICH E9 addendum (ICH 2017), this is an
example of a principal stratification estimand, where the stratum of interest is the subgroup
of the overall trial population with B(1) = 1.
2.2 Identification of the Estimand
As treatment X is randomized we know that X and the variables {T (x), β(x), Z}, x = 0, 1
are independent:
X ⊥ {T (x), β(x), Z} x = 0, 1. (3)
In what follows we will concentrate on causal identification of P (T (1) > t|B(1) = 1)
and P (T (0) > t|B(1) = 1) as ∆(t) and ∆RMST (t∗) can be derived based on these.
Note that P (T (1) > t|B(1) = 1) can be identified from the observed trial data because
P (T (1) > t|B(1) = 1) = P (T (1) > t|X = 1, B(1) = 1)
= P (T > t|X = 1, B = 1).
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The first equality holds due to randomization (3) and the second equality holds due to the
assumption of consistency, which states that the distribution of T (1)|X = 1, B(1) = 1 is
equal to the distribution T |X = 1, B = 1 observed in the trial. The quantity
P (T (0) > t|B(1) = 1), (4)
however cannot be estimated from the trial data without further causal assumptions, be-
cause in a parallel groups trial, one cannot obtain the survival time under placebo, for
patients that were on treatment and had B = 1. In the following two sections, two dif-
ferent causal assumptions will be explored that allow identification of this quantity: One
based on conditional independence assumptions using baseline covariates Z and the other
is an analysis based on the monotonicity and equi-percentile assumptions.
2.2.1 Utilization of Covariates
One approach to identify P (T (0) > t|B(1) = 1), is to utilize baseline covariates Z, so
that conditional on knowing Z, B(1) provides no further information on T (0) (and vice
versa). More formally the requirement is that T (0) and B(1) are independent conditional
on covariates Z. In formulas
T (0) ⊥ B(1) | Z. (5)
Using this assumption we have,
P (T (0) > t|B(1) = 1) =
∫
P (T (0) > t|B(1) = 1, Z)p(Z|B(1) = 1)dZ
=
∫
P (T (0) > t|Z)p(Z|B(1) = 1)dZ
=
∫
P (T (0) > t|X = 0, Z)p(Z|B(1) = 1)dZ
=
∫
P (T > t|X = 0, Z)p(Z|X = 1, B = 1)dZ
The first equation follows by the law of total probability. The second equality follows
by the assumption in (5). The third equation follows by randomization (3) and the last
equation from the consistency assumption. This equation can be estimated from the data
by estimating P (T > t|X = 0, Z), and then averaging it over the observed distribution of
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Z for the population of patients with X = 1 and B = 1 (i.e. estimating p(Z|X = 1, B = 1)
by its empirical distribution). We will discuss specific methods for estimation in Section
3.1. This approach will be called “predicted placebo response” (PPR) in the following.
Using the same arguments it follows that the probability density of the event times in
the subgroup is p(T (0)|B(1) = 1) = ∫ p(T |X = 0, Z)p(Z|X = 1, B = 1)dZ. Furthermore,∫
p(T |X = 0, Z)p(Z|X = 1, B = 1)dZ =
∫
p(T,Z|X = 0)p(Z|X = 1, B = 1)
p(Z|X = 0) dZ
=
∫
p(T,Z|X = 0)p(B = 1|Z,X = 1)p(Z|X = 1)p(X = 1)
p(Z|X = 0)p(B = 1, X = 1) dZ
∝
∫
p(T,Z|X = 0)p(B = 1|Z,X = 1)dZ (6)
The first two equations follow from the definition of conditional probability. The last
equation follows from randomization (because p(Z|X = 0) = p(Z|X = 1)) and omitting all
other terms that do not involve Z. The result in (6) is useful, because the observed data
on T, Z with X = 0 can be used to estimate p(T (0)|B(1) = 1) (and P (T (0) > t|B(1) = 1))
by utilizing the weights
w(Z) ∝ p(B = 1|X = 1, Z). (7)
The weights w(Z) can be estimated based on the patients on treatment, using, for example,
a logistic regression, or other classification approaches. We will discuss specific methods
for estimation in Section 3.2. This approach will be called “weighted placebo patients”
(WPP) in what follows.
2.2.2 Utilizing Monotonicity and Equi-Percentile Assumptions
B(0) = 1 B(0) = 0
B(1) = 1 p11 p10 p1.
B(1) = 0 p01 p00 p0.
p.1 p.0
Table 1: Principal strata
Table 1 illustrates how the overall trial population can be stratified into four subgroups
according to their potential biomarker outcomes under treatment and placebo. Here p00,
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p10, p01 and p11 denote the probabilities to fall into the relevant principal strata, {B(0) =
i ∧ B(1) = j} with i, j ∈ {0, 1}. Each patient falls in exactly one subgroup so that
p00+p10+p01+p11 = 1. Note that this classification is not known, because we only observe
one of the two potential biomarker measurements for every patient in the trial. Further
let p.j = p0j + p1j and pj. = pj0 + pj1 with a j ∈ {0, 1} be the corresponding marginal
probabilities of the table, subject to p0. + p1. = 1 and p.0 + p.1 = 1. Note that p.j and pj.
can be estimated from the observed data on placebo and active treatment, while the other
probabilities are not identifiable. To proceed further, a plausible assumption (depending
on the mechanistic understanding of the drug) is to assume that
p01 = 0, (8)
i.e., there are no patients that would be biomarker responders under placebo but not
under treatment. This so-called monotonicity assumption allows to identify that p11 = p.1,
p00 = p0. and p10 = p1. − p.1. This is useful, because (4) can be expressed as
P (T (0) > t|B(1) = 1) = P (T (0) > t|B(1) = 1)
= piP (T (0) > t|B(1) = 1, B(0) = 1) +
(1− pi)P (T (0) > t|B(1) = 1, B(0) = 0), (9)
where pi = p11
p1.
. Based on the assumption (8), the terms pi and P (T (0) > t|B(1) =
1, B(0) = 1) = P (T > t|X = 0, B = 1) in (9) are identified from the trial data.
The term P (T (0) > t|B(1) = 1, B(0) = 0) however remains unidentified in a parallel
groups trial: Among the biomarker non-responders on placebo it is not clear which would
have responded under treatment.
Due to the monotonicity assumption, we can identify all proportions pij in Table 1 and
hence also the proportion of patients p˜i among the placebo biomarker non-responders that
would have responded on treatment: p˜i = p10
p.0
= p1.−p.1
p.0
.
The task is hence to identify the patients that would be biomarker responders on
treatment among the group of placebo biomarker non-responders in order to estimate
P (T (0) > t|B(1) = 1, B(0) = 0). One approach is to assume that the biomarker outcome
β(0) on placebo contains information on the biomarker outcome under treatment (β(1) and
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more specifically the event B(1) = 1). Unfortunately we do not have data relating β(0)
and B(1), as every patient received either placebo or the treatment, hence this relationship
cannot be estimated from the observed data and will be derived using assumptions.
One simple approach is to rank patients according to their observed placebo biomarker
outcome. Then one could just select the fraction p˜i of patients with the lowest value observed
for β(0), and identify those as the ones that would be biomarker responders on treatment.
This type of assumption has in other contexts been called equi-percentile equating (see
Rubin (1991)). This approach can be criticized, because the ordering of potential biomarker
outcomes could be different under treatment and placebo. The factors leading to a low
biomarker value on placebo might be different to those on treatment. Selecting the patients
with low biomarker outcome among the placebo biomarker non-responders (and identify
those as part of the stratum B(1) = 1 ∧ B(0) = 0) will hence tend to overestimate the
survival time under placebo and thus underestimate the treatment effect.
A different idea is to include all patients among the placebo biomarker non-responders to
estimate P (T (0) > t|B(1) = 1, B(0) = 0). This will also include patients with worse health-
state, so one would expect that the event time under placebo would get underestimated
and thus the treatment effect overestimated.
We propose an analysis that interpolates between these two extremes, using a parameter,
where patients with a lower rank and thus lower observed β(0) get a higher weight than
patients with higher β(0). We propose to use the weight function ωi = 1− 11−exp(−(τi−p˜i))/δ)
for patient i, where τi is the empirical quantile for β(0) of patient i, i.e., if there are
η observations among the placebo biomarker non-responders, the patient with the i-th
ordered observation of β(0) will have an empirical quantiles of τi = i/(η + 1). See Figure
1 for an illustration of this weight function for different δ values. If δ → 0 this approach
is equivalent to using the equi-percentile equating assumption (the p˜i patients with lowest
β(0) will receive a weight of 1, while all others receive a weight of 0). Letting δ → ∞
corresponds to weighting patients equally.
To summarize the assumptions underlying this approach, we use the monotonicity as-
sumption (8) and the relaxed equi-percentile assumption, based on a logistic weighting
function. We introduced a parameter δ that interpolates between two extremes: For δ ≈ 0
8
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Figure 1: Logistic weighting function with center p˜i and different δ.
this analysis might tend to underestimate the treatment effect while for δ →∞ this analysis
will often tend to overestimate the treatment effect. This specific approach will be called
analysis based on monotonicity and equi-percentile assumption (MEA) in what follows.
3 Estimation
Different statistical models can be utilized to estimate the quantities (1) and (2). Bayesian
methods have the appeal of directly providing an uncertainty assessment, for non-Bayesian
methods bootstrap approaches can be utilized to perform inference. We focus here on semi-
parametric methods and utilize bootstrapping for inference. Nevertheless other approaches
could equally be used for estimation.
Estimation of P (T (1) > t|B(1) = 1) is straightforward by estimating P (T > t|X =
1, B = 1) from the observed data, for example, using the Nelson-Aalen estimator.
In Section 2 three methods were described to enable estimation of P (T (0) > t|B(1) = 1):
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The PPR and WPR approaches, both utilizing baseline covariates and the MEA utilizing
the monotonicity and equi-percentile assumptions, in the following sections, we summarize
the statistical analyses that can be performed to estimate the quantities needed for each
approach.
3.1 Predict placebo response (PPR)
The PPR approach requires estimation of P (T > t|X = 0, Z) (see (6)), i.e. estimation
of the survival in the placebo arm based on covariates Z. This can be done by fitting a
Cox regression in the placebo arm. An estimate for p(Z|X = 1, B = 1) can be derived by
using the empirical distribution of covariates for the biomarker responders on the treatment
arm. To derive an estimate for (4) the observed covariates Z for biomarker responders on
treatment will hence be used to predict a survival curve for every patient. This can be
done using the Breslow estimator of the baseline survival function. The estimate of (4)
is then the average of these predicted survival curves. The main modelling assumption in
this approach is that covariates enter multiplicatively on the hazard rate according to the
Cox proportional hazards model.
3.2 Weight placebo patients (WPP)
The WPP approach requires a model to determine the weights w(Z) from (7). For that
purpose a logistic regression on the treatment arm is fitted, where the outcome is the binary
indicator of the event B = 1 (being a biomarker responder) and the covariates are Z. Then
using this model, for each patient on the placebo arm the probability for B = 1 is predicted.
These probabilities are used as weights in the weighted estimation of the survival function
using a weighted Nelson-Aalen estimator in the placebo group, which is thus the estimate
of P (T (0) > t|B(1) = 1). The main modelling assumption here originates from the model
assumed for determination of w(Z), i.e. the logistic regression.
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3.3 Monotonicity and Equi-Percentile Assumption (MEA)
The MEA approach requires estimation of pi and p˜i (see Section 2.2.2). This will be done
directly from the observed proportions based on the formulas in Section 2.2.2 that follow
from the monotonicity assumption (8). For the quantity P (T (0) > t|B(1) = 1, B(0) = 1)
we have from the monotonicity assumption that P (T (0) > t|B(1) = 1, B(0) = 1) =
P (T (0) > t|B(0) = 1) = P (T > t|X = 0, B = 1) where the last equation follows by
consistency. For estimation of this quantity the Nelson-Aalen estimator will be used. The
quantity P (T (0) > t|B(1) = 1, B(0) = 0) will be estimated in the group of biomarker non-
responders on placebo, weighted according the approach outlined in Section 2.2.2, where
the weights are derived based on the biomarker value on placebo and the logistic function
with center p˜i and sensitivity parameter δ that is chosen independent of the observed data.
A weighted Nelson-Aalen estimator will be used.
4 Simulations
The purpose of this section is to evaluate the theory developed in Section 2 for a particular
data generating true model.
We will generate data for a parallel groups, event-driven randomized trial to compare
active treatment against placebo. The simulation is loosely motivated by the CANTOS
trial mentioned in Section 1, even though a few details used here are different. It is
assumed that around 20% of the patients will have an event by year 5. The analysis will
be performed, once 850 events have been observed in total. Patients that did not have
an event by this calendar time will be censored. The number of 850 events is chosen as
this is approximately the number needed to detect a log-hazard ratio of 0.8 based on the
log-rank test with significance level 0.05 and power 0.9. Recruitment will be simulated
according to a homogeneous Poisson process, that is, enrollment is assumed to be linear
increasing over time (uniformly distributed entry times). The yearly recruitment rate is
set to be 1500 patients. For every patient we utilize two baseline covariates, Z0 and Z1 (in
a real situation Z would of course be higher-dimensional). Here, Z0 is assumed to be the
biomarker value at baseline and Z1 a general covariate that has a strong prognostic effect on
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the event time, and small effect on the post-baseline biomarker. For Z0 and Z1 we assume
a bivariate normal distribution with means 0, standard deviations 1 and correlation of 0.25.
The post-baseline biomarker level β for patient i is then simulated from the following linear
model
βi ∼ N(µi, 1) with µi = α0 + α1Xi + α2Z0,i + α3Z1,i (10)
where Z0,i, Z1,i and Xi are the observed baseline covariates and the treatment indicator for
patient i. In the simulations the parameters α = (α0, α1, α2, α3) will be chosen to represent
a typical situation where there is a strong effect of treatment and baseline biomarker value
Z0 on the post-baseline biomarker, but only a small effect of the covariate Z1. The specific
values assumed are α0 = 1, α1 = −1.75, α2 = 0.5 and α3 = 0.1.
The event time Ti for patient i will be generated based on the post-baseline biomarker
value βi for every patient as
Ti ∼ Exponential(λi) with λi = exp(γ0 + γ1Z0,i + γ2Z1,i + γ3Xi + γ4βi + γ5βiXi). (11)
The parameters γ = (γ0, γ1, γ2, γ3, γ4, γ5) are chosen as follows: γ0 is chosen so that at 5
years an event rate of 20% is achieved (if all other covariates would be 0). The parameters γ1
and γ2 represent the prognostic effect of the baseline variables, for γ1 a value of − log(0.95)
will be chosen, indicating a small effect the baseline biomarker level and for γ2 − log(0.5)
indicating a strong effect of this prognostic covariate.
The parameters γ3, γ4 and γ5 describe the treatment effect: γ3 denotes the effect of
treatment independent of the post-baseline biomarker level, γ4 is the effect of the post-
baseline biomarker level β, while γ5 determines, how much the treatment effect is modified
by the post-baseline biomarker level. Different scenarios will be evaluated for γ3, γ4 and
γ5, corresponding to different assumptions on how the treatment effect is generated: (i)
for γ3 6= 0, γ4 = γ5 = 0 the post-baseline biomarker value has no effect on the outcome,
and the treatment works only by other mechanisms, (ii) for γ4 6= 0, γ3 = γ5 = 0 all the
treatment effect is achieved through the modification of the biomarker, and (iii) γ3 = 0
and γ4, γ5 6= 0 corresponds to situation (ii), but the treatment effect is modified by the
post-baseline biomarker level. In each case the parameters γ3, γ4, γ5 are chosen such that
difference in the average log hazard rates between treatment and placebo group is equal to
log(0.8), to ensure that the overall “treatment effect” is similar across the scenarios. The
12
exact parameters values are given in Table 3 in Appendix A.1. A detailed algorithm of how
the event-driven trials are generated, is given in Appendix A.2.
For the simulation we will set the biomarker threshold at 0, i.e., we focus on the
subgroup of patients that achieve a post-baseline biomarker value less than 0 on treatment.
From model (10) for the post-baseline biomarker and with parameters as in Appendix A.1,
the probability to achieve β < 0 on treatment is around 75% and around 19% on placebo.
We estimate the difference in restricted survival time ∆RMST,t∗ with t
∗ = 5. For esti-
mation of the difference in survival ∆(t) we utilize t = 2, 5.
We compare six approaches: PPR, WPP and MEA (with δ = 0.05 and δ = 50) and
two further analyses which are simple and seemingly intuitive to do, but do not target the
estimand of interest. The first additional method estimates the placebo survival curve in
the subgroup of interest by utilizing the complete placebo group (called NAIVE FULLPBO
in what follows). The second approach only utilizes placebo patients, which have β < 0
on placebo (NAIVE THRES). As discussed in the introduction, the NAIVE FULLPBO
approach is expected to over-estimate the treatment effect (as the baseline population on
the combined placebo group is “less healthy”), while for the NAIVE THRES approach one
would expect that it underestimates the treatment effect (as the baseline population of
patients on the placebo arm that reach the threshold is “healthier”).
To evaluate how well the different approaches estimate the estimands of interest (dif-
ference in survival curve and restricted mean survival time), we need to derive the “true”
survival curves on treatment and placebo in the subgroup of interest. In Appendix A.3 this
is explained in detail.
In each scenario 5000 simulations were performed and Figure 2 displays boxplots for
the estimation error of the difference in the restricted mean survival time up to year 5
(∆RMST,5). As expected the naive approaches systematically over- (NAIVE FULLPBO) or
underestimate (NAIVE THRES) the difference in restricted mean survival times, with the
NAIVE THRES approach having a much larger variability (due to the small sample size
on placebo).
For the MEA approach one can see that for our simulation settings the method with
δ = 50 one obtains estimates that tend to overestimate the treatment effect, as expected.
13
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Figure 2: Boxplot of difference between true and estimated difference in the mean restricted
survival time (RMST) up to year 5.
The performance for δ = 0.05 is adequate in scenario (i), where the outcome is independent
of the post-baseline biomarker. For scenarios (ii) and (iii) the treatment effect is under-
estimated on average. This is because the equi-percentile assumption is violated in these
scenarios (see also Appendix A.3 on how the true survival differences were calculated).
The WPP and PPR perform well across all scenarios. This is expected as these approaches
utilize the information on the true covariates (and in this sense also the true simulation
model).
Overall similar results can also be observed for estimation of the survival differences
∆(t = 2) and ∆(t = 5), see Figures 5 and 6 in the Appendix.
Note that for the considered simulation setting is simple, but the purpose here was to
investigate our semiparametric procedures in this case, where naive approaches already fail.
5 Data application
For illustration we analyse a data set simulated under scenario (iii) above. In the simulated
data set 850 events were reached after 5.9 years. The mean follow-up time for patients was
around 3.9 years at that time.
Figure 3 shows four observed cumulative incidence rates 1−(estimated survival func-
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Figure 3: Observed cumulative incidence rates.
tion), estimated using the Nelson-Aalen estimator. Two curves correspond to the overall
estimates in the placebo and treatment groups. The other two curves correspond to pa-
tients on placebo and treatment with β < 0. About 20% of the patients on placebo reached
this value and about 76% of the patients on treatment. Figure 3 shows that there were
less events on the active treatment and also that a low biomarker post-baseline leads to a
smaller event rate.
Figure 4 shows six approaches to estimate the difference in the cumulative incidence
rate. The first two are the PPR and WPP approaches discussed in Section 2. In addition
we show four principal stratification approaches with the different δ values shown in Figure
1. Note that all six approaches only differ in the way that the placebo survival curve is
estimated. The estimation of the survival curve in the subgroup of interest under treatment
is the same for all approaches. The results are quite consistent with the simulation results
in the previous section in the sense that the PPR and WPP approaches lead to quite similar
results and the MEA approaches estimate an increased treatment effect with increasing δ
as expected.
Table 2 presents numerical results for the PPR, WPP and MEA approaches for estima-
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tion of the survival differences ∆(2), ∆(5) and ∆RMST,5. Confidence intervals have been
calculated using sampling with replacement stratified by treatment group (non-parametric
bootstrap).
One can see that in all cases and for all estimands of interest the confidence interval
excludes 0, so a treatment effect is concluded in this setting, which is the right decision
based on the simulation scenario upon which the data were generated.
6 Conclusions
In this paper we considered estimation of the treatment effect in a subgroup defined by
reaching a post-baseline biomarker measurement on treatment. This is challenging, because
in a parallel groups trial we do not observe the event time that these patients would have
had, had they been randomized to the placebo group. Three approaches are proposed
based on different causal identifying assumptions. Two approaches (PPR and WPP) are
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Method ∆(2) ∆(5) ∆RMST,5
WPP 0.026 (0.01,0.04) 0.064 (0.039,0.09) 0.183 (0.114,0.248)
PPR 0.027 (0.012,0.042) 0.066 (0.043,0.093) 0.191 (0.123,0.256)
MEA, δ = 0.05 0.026 (0.01,0.042) 0.064 (0.037,0.09) 0.178 (0.103,0.245)
MEA, δ = 0.15 0.027 (0.011,0.042) 0.065 (0.039,0.09) 0.182 (0.111,0.249)
MEA, δ = 0.5 0.028 (0.013,0.044) 0.069 (0.045,0.093) 0.196 (0.128,0.265)
MEA, δ = 50 0.031 (0.016,0.046) 0.073 (0.048,0.096) 0.211 (0.145,0.28)
Table 2: Point estimates with 90% bootstrap quantile confidence intervals for the quantities
of interest.
based on a conditional independence assumption utilizing baseline covariates, stating that
given a set of baseline covariates the potential biomarker outcome under treatment and the
potential event time under placebo are independent. Utilizing this, one can use placebo
information to estimate the placebo response for the patients in the subgroup of interest.
The third approach (MEA) is based on principal stratification and utilizes the monotonicity
and a relaxed equi-percentile assumption with a logistic weighting function based on a
sensitivity parameter δ. The approaches have been evaluated in a simulation study, where
the proposed approaches show good performance compared to more naive approaches.
Finally the methodology has been illustrated on a single simulated data set.
In this paper we estimated the survival difference at a specified time and on estimation
of the mean restricted survival time, both quantities are rather easy to interpret. In many
clinical applications the hazard ratio is the measure to compare time-to-event endpoints,
with the underlying assumption that the hazards are proportional. In our setting we do not
make the assumption of proportional hazards and estimate the survival curves separately
for placebo and treatment. Hence it is not immediately obvious how to summarize the
ratio of hazard functions into a single hazard ratio. A graphical approach would be to plot
the ratio of the cumulative hazard functions, which is easily obtainable from the already
determined survival functions, to see whether values fluctuate around a particular value.
In cases like the simulated example above (see Section 5), where there is a rather low event
rate, and the cumulative hazard functions are approximately linear (like in Figure 3), one
approach is to fit a simple exponential (exp(−λt)) to the survival curves and then derive
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an approximate hazard ratio based on the ratio of the fitted rates.
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Scenario Values
(i) γ3 6= 0, γ4 = γ5 = 0 γ3 = log(0.8)
(ii) γ3 = γ5 = 0, γ4 6= 0 γ4 = 0.1275
(iii) γ3 = 0, γ4, γ5 6= 0 γ4 = 0.06375, γ3 = 0.1489
Table 3: Parameter values for γ utilized in the three simulation scenarios.
A Simulations
A.1 True data-generating parameters
For the parameter γ the scenarios outlined in Table 3 will be utilized.
A.2 Data generation for event-driven trial
The following steps explain how the survival data were generated in the simulation study.
• Input
λ0: enrollment rate per year
pY and Y : A fraction of pY of the subjects on placebo will have an event by year Y
ne number of events
α,γ: parameters for the models of the post-baseline biomarker and the event-time
• Calculate N∗ = [ne/pY ], the approximate number needed to recruit to achieve ne
events by year Y .
• For each patient simulate the following random variables (i.e. N∗ in total)
– Generate N∗ i.i.d. exponential random variates with hazard rate λ0 and sort
them in increasing order, to obtain the recruitment times for every patient
– Generate baseline variables (Z0, Z1)
i.i.d.∼ MVN(µ,Σ) with mean vector equal to
0, marginal variances 1 and correlation 0.25.
– treatment indicator X
i.i.d.∼ B(1, 0.5)
– post-baseline biomarker value β according to the linear model (10) with param-
eters α and covariates values as generated in the previous steps.
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– the event time from the exponential model (11) with parameters γ and covariates
values as generated in the previous steps.
• Calculate the calendar times for the event times (i.e. for every patient add recruit-
ment and event time).
• Determine by which calendar time 850 patients had the event. Remove all patients
that were recruited after this calendar time. The event times of patients that had
their event-time after this calendar time are right-censored with this as their censoring
time. For analysis translate all times back to the study time.
A.3 Calculation of true survival curves in subgroup of interest
In the data-generating model used in our simulations (Equations (10), (11)) the subgroup
of patients of interest (i.e. those that achieve β < 0 on treatment) can explicitly be
characterized in terms of the baseline covariates Z0 and Z1: The joint distribution of
Z0 and Z1 conditional on β < 0 and X = 1 can be simulated by simulating the joint
distribution given X = 1, and then removing the observations where β ≥ 0.
Having obtained this joint distribution for Z0, Z1 and β in the subgroup of interest
(patients with β < 0), these values can be plugged in the true exponential survival curve
(see (11)) and the resulting survival curves averaged, to obtain the population survival
curve under treatment. To obtain the population survival curve under placebo a biomarker
outcome under placebo is first simulated for each patient based on their covariates Z0,
Z1 (according to (10)) and then Z0, Z1 and the simulated biomarker value under placebo
are plugged in the true exponential survival curve. The resulting survival curves are then
averaged, to obtain the population survival curve under treatment.
21
l ll ll lll ll lll
lll ll l lll lll l
ll lll ll ll l lll
l lll l lll ll l
l lll l ll ll
l l ll ll lll lll ll ll
lllll ll ll l
l ll ll ll l lll
l ll llll ll
l l lll lllll l
l ll l lll ll ll
ll l ll ll ll ll l
ll lll l ll llll
l ll llll lll
ll ll lll ll ll lll
ll ll ll lll ll
ll lll l llll ll
ll l lll lll ll ll
(i) (ii) (iii)
−0.09 −0.06 −0.03 0.00 0.03 0.06−0.09 −0.06 −0.03 0.00 0.03 0.06−0.09 −0.06 −0.03 0.00 0.03 0.06
PPR
WPP
MEA(delta=0.05)
MEA(delta=50)
NAIVE_FULLPBO
NAIVE_THRES
Estimation Error of Survival Difference for Year=2
Figure 5: Estimation error for estimation of the difference in the survival curves at time
point 2.
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Figure 6: Estimation error for estimation of the difference in the survival curves at time
point 5.
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A.4 Additional Simulation Results
B Events before T and missing post-baseline biomarker
measurements
The time-point T of measuring the post-baseline biomarker, should be relatively short after
initiation of treatment. A subgroup defined based on a biomarker measurement at a time-
point far away from baseline, will not be of clinical interest. Thus in general few events will
be expected before T , and unlikely to influence the overall analysis much. Nevertheless in
many practical situations there will be some events and in this section we will discuss how
to formally handle these situations. Another related issue that we will discuss, are missing
post-baseline biomarker values (i.e. situations where a biomarker value could have been
measured at time T but was not).
An important consideration in handling events before time T in the case of composite
events is to distinguish between death and non-fatal events. Let the time to death be TD.
In general the subgroup of interest should then be defined by B(1) = 1 and TD(1) > T ,
i.e., the subgroup of patients, who would, on treatment, be alive and biomarker responders.
An assumption that is plausible in some situations is to assume that TD(1) > T implies
TD(0) > T and vice-versa. That is, patients not dying under treatment before time T
would also not have died under placebo (and vice versa). This assumption would justify
an analysis, where patients dying before T are excluded from the analysis and approaches
suggested in Section 2 could be performed as they are described. If it is assumed that the
population of patients dying before time T is different between treatment and placebo,
the analyses would need to be modified, to identify/weight patients on the placebo arm,
according to whether they would have died on the treatment arm until time T .
In principle non-fatal events could be handled in exactly the same way. One could define
the subgroup by B(1) = 1 and T (1) > T , i.e., the subgroup of patients, who would, on
treatment, be event-free and biomarker responders. Whether or not this is more relevant
than the subgroup B(1) = 1 and TD(1) > T is a clinical and pharmacological question: Are
non-fatal events likely due to the fact that the drug “does not work” (i.e. supporting the
decision of stopping the treatment after the event, which would mean it is more relevant
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to focus on the subgroup B(1) = 1 and T (1) > T ), or is it too early to say that, because
the drug effect did not fully materialize by time T . If it is considered relevant to continue
treating patients even in case of an event up to time T the more relevant subgroup would
be given by B(1) = 1 and TD(1) > T . In this situation the approach would be to include
the events before T in the analysis.
A different issue is that there will always be patients, where the post-baseline biomarker
measurement is missing, but in principle measurable. It is not appropriate to remove these
patients from the analysis, as these might be systematically different from the popula-
tion of patients, where the biomarker measurement is available. One way of approaching
this, is to impute missing post-baseline biomarker values, using for example the baseline
biomarker level as well as other covariates to impute the post-baseline biomarker value on
treatment. Given each completed multiply-imputed data set, the rest of the analysis would
be conducted as described in Sections 2 and 3 and at the end appropriately combined.
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